Evidence map›Paper›PMID 41492190›Full record

ReviewClinical and molecular hepatology2026

Clinical applications of immunogenomics in hepatocellular carcinoma.

James K Carter, Daniel C Cameron, Augusto Villanueva

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and molecular hepatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

James K CarterDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Daniel C CameronApplied Bioinformatics Laboratories, NYU Grossman School of Medicine, New York, NY, USA.
Augusto VillanuevaDivision of Gastroenterology and Hepatology, Department of Medicine, Perlmutter Cancer Center, NYU Grossman School of Medicine, New York, NY, USA.

Funding

Astra ZenecaCarisGenentechMedpaceNIH HHS 1U01CA283931
6 · The paper itself

Abstract

Liver cancer is one of the deadliest malignancies, with increasing incidence worldwide. Recent advances in immunotherapy have expanded the options for systemic therapy against advanced hepatocellular carcinoma (HCC), but there are no biomarkers currently available to predict which patients will respond, leading to suboptimal patient selection strategies. Understanding of the genetic and immunologic features of HCC is accelerating rapidly through the use of single cell and spatial transcriptomic techniques. However, there is a need to translate insights gained through these new studies to improve treatment options and improve patient selection. In this review we summarize knowledge of the immunogenomics of HCC, emphasizing recent advances, and discuss progress toward clinical translation.

Indexed as

Carcinoma, HepatocellularImmunogeneticsLiver NeoplasmsBiomarkers, TumorHumansImmunotherapyBiomarkers, TumorGenomic medicineHepatocellular carcinomaImmune checkpoint inhibitorsPrecision medicineTumor microenvironment

Identifiers

PMID41492190
PMCPMC13129791

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.